Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 2
1997 3
1998 4
1999 8
2000 28
2001 152
2002 320
2003 549
2004 562
2005 611
2006 679
2007 808
2008 736
2009 792
2010 782
2011 799
2012 786
2013 717
2014 685
2015 557
2016 528
2017 491
2018 434
2019 237
2020 12
Text availability
Article attribute
Article type
Publication date

Search Results

10,054 results
Results by year
Filters applied: . Clear all
Page 1
Imatinib mesylate-induced lichenoid drug eruption.
Penn EH, Chung HJ, Keller M. Penn EH, et al. Cutis. 2017 Mar;99(3):189-192. Cutis. 2017. PMID: 28398413 Review.
Imatinib Mesylate.
Waller CF. Waller CF. Recent Results Cancer Res. 2018;212:1-27. doi: 10.1007/978-3-319-91439-8_1. Recent Results Cancer Res. 2018. PMID: 30069623
The argument for using imatinib in CML.
Claudiani S, Apperley JF. Claudiani S, et al. Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):161-167. doi: 10.1182/asheducation-2018.1.161. Hematology Am Soc Hematol Educ Program. 2018. PMID: 30504305 Free PMC article. Review.
Pharmacology and pharmacokinetics of imatinib in pediatric patients.
Suttorp M, Bornhäuser M, Metzler M, Millot F, Schleyer E. Suttorp M, et al. Expert Rev Clin Pharmacol. 2018 Mar;11(3):219-231. doi: 10.1080/17512433.2018.1398644. Epub 2017 Nov 6. Expert Rev Clin Pharmacol. 2018. PMID: 29076384 Review.
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.
Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, Ortmann CE, Menssen HD, Kantarjian H, O'Brien SG, Druker BJ; IRIS Investigators. Hochhaus A, et al. N Engl J Med. 2017 Mar 9;376(10):917-927. doi: 10.1056/NEJMoa1609324. N Engl J Med. 2017. PMID: 28273028 Free PMC article. Clinical Trial.
A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-β.
Yam C, Murthy RK, Rauch GM, Murray JL, Walters RS, Valero V, Brewster AM, Bast RC Jr, Booser DJ, Giordano SH, Esteva FJ, Yang W, Hortobagyi GN, Moulder SL, Arun B. Yam C, et al. Invest New Drugs. 2018 Dec;36(6):1103-1109. doi: 10.1007/s10637-018-0672-z. Epub 2018 Oct 11. Invest New Drugs. 2018. PMID: 30311036 Clinical Trial.
Association of oral mucosa hyperpigmentation with imatinib mesylate use: a cross-sectional study and a systematic literature review.
Oliveira SR, de Azevedo Branco LG, Rocha AL, Travassos DV, Magalhães GHR, Fonseca FP, Mesquita RA, Abreu LG, da Silva TA. Oliveira SR, et al. Clin Oral Investig. 2019 Dec;23(12):4371-4382. doi: 10.1007/s00784-019-02886-0. Epub 2019 Apr 9. Clin Oral Investig. 2019. PMID: 30968242
10,054 results
Jump to page
Feedback